Lumos Diagnostics Holdings Ltd.ASX: LDX

Quarterly Activities/Appendix 4C Cash Flow Report

· Issued by Lumos Diagnostics Holdings Ltd. via ASX

Filed with ASX ·

ASX ANNOUNCEMENT Lumos Diagnostics Quarterly Activity Statement, Cash Flow and FebriDx® Commercial Update Key Highlights from the First Quarter of Financial Year 2027 • U.S. commercialisation of FebriDx® as of 11 October 2026 - 265 healthcare sites across 29 states 1 actively ordering and using...

View Attachment

6ix is reading this filing.

Lumos Diagnostics Holdings Ltd. on 6ix

In the deck

Earlier from Lumos Diagnostics

All Lumos Diagnostics news releases